All Stories

  1. CD95L concatemers highlight different stoichiometries of CD95‐mediated apoptotic and non‐apoptotic pathways
  2. CD95L concatemers highlight difference in the manner CD95-mediated apoptotic and non-apoptotic pathways are triggered
  3. Ambivalent role of FasL in murine acute graft-versus-host-disease
  4. MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways
  5. Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network
  6. Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors
  7. Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii
  8. Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity
  9. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
  10. CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism
  11. CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
  12. Single bilateral ovarian venous return in uterine transplant: Validation in an orthotopic auto-transplant model in the Yucatan minipig
  13. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis
  14. Editorial: Death Receptors, Non-apoptotic Signaling Pathways and Inflammation
  15. CD95 Structure, Aggregation and Cell Signaling
  16. Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
  17. Editor's Note: Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP
  18. The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
  19. Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction
  20. Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
  21. Correction: The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway
  22. Investigation of Phospholipase Cγ1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors
  23. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer
  24. HIV protease inhibitors and autoimmunity: An odd, but promising idea
  25. Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis
  26. CD95/Fas and metastatic disease: What does not kill you makes you stronger
  27. Staphylococcus aureus induces DNA damage in host cell
  28. An insight into the role of the death receptor CD95 throughout pregnancy: Guardian, facilitator, or foe
  29. Chemical Composition, Antioxidant, and Anticancer Effect of Ruta chalepensis’s Extracts against Human Leukemic Cells
  30. Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation
  31. Ovarian Cancer Immunity
  32. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy
  33. Tumor analysis: freeze–thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells
  34. Nonapoptotic functions of Fas/CD95 in the immune response
  35. CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases
  36. Chemical composition, antioxidant, and anticancer effect of Ruta chalepensis’s extracts against human leukemic cells
  37. FAS (Fas cell surface death receptor)
  38. T cell landscape in triple negative breast cancer patients
  39. Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L
  40. Erratum
  41. CD95
  42. CD95 Stimulation with CD95L and DISC Analysis
  43. Proximity Ligation Assay (PLA) to Evaluate DISC and MISC Composition
  44. Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K
  45. Atypical Immune Functions of CD95/CD95L
  46. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
  47. Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?
  48. How mTOR inhibitors show some success in clinical trials
  49. Cyaneodimycin, a Bioactive Compound Isolated from the Culture ofStreptomyces cyaneofuscatusAssociated withLichina confinis
  50. CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice
  51. The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca2+ flux from the endoplasmic reticulum to mitochondria
  52. The cleaved FAS ligand activates the Na+/H+ exchanger NHE1 through Akt/ROCK1 to stimulate cell motility
  53. Sphingolipids modulate the epithelial–mesenchymal transition in cancer
  54. Meet Our Editorial Board Member:
  55. Chemotherapy with ceramide in TNBC
  56. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
  57. The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
  58. The CD95/CD95L signaling pathway: A role in carcinogenesis
  59. Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility
  60. CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
  61. Staphylococcus aureus-Induced G2/M Phase Transition Delay in Host Epithelial Cells Increases Bacterial Infective Efficiency
  62. Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity
  63. Precise Mapping of the CD95 Pre-Ligand Assembly Domain
  64. Guidelines for the use and interpretation of assays for monitoring autophagy
  65. The CD95 signaling pathway
  66. CD95 triggers Orai1-mediated localized Ca2+entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation
  67. CD95-mediated cell signaling in cancer: mutations and post-translational modulations
  68. Editorial [Hot topic: Stresses, Death Receptors and Plasma Membrane (Guest Editors: Patrick Legembre and Faustino Mollinedo)]
  69. Actin-independent exclusion of CD95 by PI3K/AKT signalling: Implications for apoptosis
  70. Does calcium contribute to the CD95 signaling pathway?
  71. The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway
  72. S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligand–Mediated Apoptosis in Cancer Cells
  73. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells
  74. Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?
  75. CD95 engagement mediates actin-independent and -dependent apoptotic signals
  76. The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells
  77. An atypical necrotic signal induced by immunosuppressive and anti-viral agents
  78. Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway
  79. Rewinding the DISC
  80. The HA tag is cleaved and loses immunoreactivity during apoptosis
  81. Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP
  82. Corrigendum to “Does CD95 have tumor promoting activities?” [Biochim. Biophys. Acta 1755 (2005) 25–36]
  83. Amplification of Fas-Mediated Apoptosis in Type II Cells via Microdomain Recruitment
  84. Does CD95 have tumor promoting activities?
  85. Induction of apoptosis and activation of NF‐κB by CD95 require different signalling thresholds
  86. The relevance of NF-?B for CD95 Signaling in Tumor Cells
  87. Identification of SNF1/AMP Kinase-related Kinase as an NF-κB-regulated Anti-apoptotic Kinase Involved in CD95-induced Motility and Invasiveness
  88. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells
  89. Two CD95 tumor classes with different sensitivities to antitumor drugs
  90. Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism
  91. Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas